A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
M15-654
NCT03314181
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
KCP-330-017 (STOMP)
NCT02343042
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Myeloma |
Dr. Marc Lalancette
Diane Bernard
418-525-4444 poste 15782
Patricia Chabot
418-525-4444 poste 15769
|
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
NCI M4
NCT03421132
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Nathalie Lachapelle
514-252-3400 poste 4471
|
A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Nathalie Lachapelle
514-252-3400 poste 4471
|
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
EFC15951
NCT05405166
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
|
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
NCI M4
NCT03421132
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A phase I, open label study to evaluate the safety, pharmacokinetic, pharmacodynamic and clinical activity of PF-06863135, a B-cell maturation antigen (BCMA) - CD3 bispecific antibody, as a single agent and in combination with immunomodulatory agents in patients with relapsed/refractory advanced multiple myeloma
C1071001
NCT03269136
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma
DREAMM-6
NCT03544281
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody in Subjects With Relapsed or Refractory Multiple Myeloma
64007957MMY1001
NCT04557098
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
CC-220-MM-001
NCT02773030
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
Groupe d'étude en oncologie du Québec